Altamira up on nasal spray re-launch in Europe

Altamira Therapeutics

27/09/2022 16:37

** Shares of biotech co Altamira Therapeutics Ltd  CYTO.O 
rise nearly 12% to $0.28 
    ** Co's U.S. FDA-approved anti-allergy nasal spray Bentrio
will be re-launched in Europe, initially in Germany, beginning
in early October  urn:newsml:reuters.com:*:nGNX90P5L9
    ** CYTO will market Bentrio to help in treating allergic
symptoms caused by airborne allergens like pollen and house dust
bugs 
    ** Co had recently stopped marketing Bentrio for another
indication in EU and Switzerland
    ** Including session's gain, stock still down 86% YTD 
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))